Compare AEIS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEIS | IBRX |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 8.2B |
| IPO Year | 1996 | 2015 |
| Metric | AEIS | IBRX |
|---|---|---|
| Price | $224.53 | $8.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $415.00 | $14.25 |
| AVG Volume (30 Days) | 573.7K | ★ 13.3M |
| Earning Date | 11-02-2026 | 11-13-2026 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ 168.53 | 38.71 |
| EPS | ★ 2.86 | N/A |
| Revenue | ★ $453,095,000.00 | $113,288,000.00 |
| Revenue This Year | $34.79 | $99.98 |
| Revenue Next Year | $24.79 | $108.29 |
| P/E Ratio | $77.66 | ★ N/A |
| Revenue Growth | 38.39 | ★ 668.31 |
| 52 Week Low | $187.71 | $1.95 |
| 52 Week High | $397.44 | $12.43 |
| Indicator | AEIS | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 42.43 |
| Support Level | $210.50 | $7.72 |
| Resistance Level | $350.63 | $8.56 |
| Average True Range (ATR) | 11.99 | 0.71 |
| MACD | -1.09 | -0.13 |
| Stochastic Oscillator | 28.11 | 12.82 |
Advanced Energy Industries Inc provides precision power conversion, measurement, and control solutions. The company designs, manufactures, sells, and services power electronics conversion products that transform raw electrical power into controllable, usable power for complex equipment. It operates in one reporting segment, Power Electronics Conversion Products, serving the Semiconductor Equipment, Data Center Computing, Industrial and Medical, and Telecom and Networking markets. Its products include Plasma Power Products, AC-DC Power Supply Units, DC-DC Converters, High Voltage solutions, SCR Power Controllers, and Sense and Measurement solutions. The company operates in the United States, Asia, Europe, and other regions.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.